Company / FCF Margin
Ultragenyx Pharmaceutical Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-70.1%
FY2025
5-year range
-357.0% / -70.1%
FY2021-FY2025
Trend
+6.7%
vs FY2024
Sector context
#84 of 134
Health Care
What the data says
At -70.1%, Ultragenyx Pharmaceutical Inc.'s fcf margin ranks #84 of 134 in the Health Care sector. FCF Margin has increased for 6 consecutive years, from -9825.3% in FY2019 to -70.1% in FY2025.
Based on SEC 10-K filings.
-70.1% in FY2025 with a 5-year CAGR of +502.1%.
Improved from -119.6% to -70.1% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +66.5pp
- 5-Year Change
- +502.1pp
- 10-Year Change
- -
Sector benchmark
#84 of 134 in Health CareTop 63% of 134This company -70.1% Sector average -637.8%
▼
+89.0% above sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s fcf margin has grown for 6 consecutive years.
- In FY2025, fcf margin increased 6.7% year-over-year.
- Currently 567.6pp above the Health Care sector average.
- Lowest fcf margin in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -70.1% | +6.7% |
| FY2024 | -75.2% | +37.1% |
| FY2023 | -119.6% | +12.5% |
| FY2022 | -136.7% | +61.7% |
| FY2021 | -357.0% | +37.6% |
| FY2020 | -572.2% | +94.2% |
| FY2019 | -9825.3% | -1617.2% |
| FY2018 | -572.2% | +99.3% |
| FY2017 | -83407.5% | +69.7% |
| FY2016 | -275194.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026